logo

ASTH

Astrana Health·NASDAQ
--
--(--)
--
--(--)
9.72 / 10
Outperform

ASTH's fundamental score is 9.7/10, reflecting excellent standing. Strengths include high Asset-MV (3/3) and Cash-MV (2/3) quality ratings, and a strong Net cash flow from operating activities per share (3/3). However, Revenue-MV (1/3) and Net income-Revenue (0/3) are weaker, and all earnings-per-share metrics are negative (0/3), indicating growth challenges. Historical back-tests show mixed returns: Asset-MV and Cash-MV have moderate positive one-month returns (4.29% and 2.59% respectively), while negative earnings metrics yield negative returns (-3.08% to -6.7%). This suggests solid asset and cash positions but lagging revenue and profitability growth, warranting caution on long-term earnings sustainability.

Fundamental(9.72)SentimentTechnical

Analysis Checks(4/10)

Revenue-MV
Value1.52
Score1/3
Weight7.53%
1M Return0.59%
Net cash flow from operating activities per share (YoY growth rate %)
Value80.01
Score3/3
Weight72.56%
1M Return5.16%
Net income-Revenue
Value-4.67
Score0/3
Weight-2.52%
1M Return-0.21%
Basic earnings per share (YoY growth rate %)
Value-67.62
Score0/3
Weight-30.46%
1M Return-3.08%
Total profit (YoY growth rate %)
Value-61.19
Score0/3
Weight-44.30%
1M Return-4.70%
Net cash flow from operating activities (YoY growth rate %)
Value86.05
Score3/3
Weight74.24%
1M Return5.21%
Diluted earnings per share (YoY growth rate %)
Value-68.27
Score0/3
Weight-29.57%
1M Return-3.01%
Asset-MV
Value-0.50
Score3/3
Weight57.91%
1M Return4.29%
Net profit attributable to parent company shareholders (YoY growth rate %)
Value-67.09
Score0/3
Weight-35.98%
1M Return-3.80%
Cash-MV
Value-1.58
Score2/3
Weight30.57%
1M Return2.59%
Is ASTH fundamentally strong?
  • ASTH scores 9.72/10 on fundamentals and holds a Discounted valuation at present. Backed by its 3.09% ROE, 0.34% net margin, 41.90 P/E ratio, 1.91 P/B ratio, and -84.73% earnings growth, these metrics solidify its Outperform investment rating.